
Sign up to save your podcasts
Or
Ambassador Alon Pinkas, former Israel General Consel in New York, former Chief of Staff to two foreign minister, and former advisor on US affairs to former Israeli Prime Minister Ehud Barak, joins to discuss the latest on the Israel-Hamas war. Bloomberg’s Alix Steel and Guy Johnson interview Chevron CEO Mike Wirth and Hess CEO John Hess on their merger. RJ Gallo, Senior Portfolio Manager, Fixed Income at Federated Hermes, joins to discuss the bond rout and outlook for the bond market. Elizabeth Hurd, Chair of Religious Studies and Professor of Political Science at Northwestern, joins to contextualize the history and geopolitics of the Israel-Hamas war. Fraser Atkinson, CEO of Greenpower Motor Company (NASDAQ: GP), joins to discuss his company’s aim to make battery-electric buses and trucks affordable and other green power initiatives. Joel Lewis, CEO at Galectin Therapeutics (NASDAQ: GALT), joins to discuss his firm, medical trials, and the market potential for their current drug development. Hosted by Paul Sweeney and Matt Miller.
See omnystudio.com/listener for privacy information.
3.8
372372 ratings
Ambassador Alon Pinkas, former Israel General Consel in New York, former Chief of Staff to two foreign minister, and former advisor on US affairs to former Israeli Prime Minister Ehud Barak, joins to discuss the latest on the Israel-Hamas war. Bloomberg’s Alix Steel and Guy Johnson interview Chevron CEO Mike Wirth and Hess CEO John Hess on their merger. RJ Gallo, Senior Portfolio Manager, Fixed Income at Federated Hermes, joins to discuss the bond rout and outlook for the bond market. Elizabeth Hurd, Chair of Religious Studies and Professor of Political Science at Northwestern, joins to contextualize the history and geopolitics of the Israel-Hamas war. Fraser Atkinson, CEO of Greenpower Motor Company (NASDAQ: GP), joins to discuss his company’s aim to make battery-electric buses and trucks affordable and other green power initiatives. Joel Lewis, CEO at Galectin Therapeutics (NASDAQ: GALT), joins to discuss his firm, medical trials, and the market potential for their current drug development. Hosted by Paul Sweeney and Matt Miller.
See omnystudio.com/listener for privacy information.
1,200 Listeners
431 Listeners
2,174 Listeners
992 Listeners
1,795 Listeners
966 Listeners
196 Listeners
1,029 Listeners
181 Listeners
1,267 Listeners
65 Listeners
80 Listeners
31 Listeners
62 Listeners
2 Listeners
56 Listeners
2 Listeners
50 Listeners
7 Listeners
198 Listeners
12 Listeners
232 Listeners
54 Listeners
70 Listeners
17 Listeners
54 Listeners
85 Listeners
371 Listeners
47 Listeners